GlassScriptPhysician profile
Fredericka C Lockett
NPI 1598714065
$874.36
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.87 · 2020: $401 · 2021: $415 · 2022: $30.50.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $206.64 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $170.06 | 2021 | |
| Pfizer INC. | $146.95 | 2020-2021 | |
| Allergan, INC. | $106.58 | 2020 | |
| Abbvie INC. | $60.26 | 2021 | |
| Sanofi-Aventis U.S. LLC | $54.06 | 2020-2021 | |
| Abbott Laboratories | $43.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.40 | 2020 | |
| Dexcom, INC. | $14.08 | 2021 | |
| Glaxosmithkline, LLC. | $13.39 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredericka Lockett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.